Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Open-label, Non-comparative Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Candidiasis or Candidemia (CFDA Commitment)

NCT01982071 is registered in ClinicalTrials.gov with Astellas Pharma China, Inc. as lead sponsor.

NCT NCT01982071
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01982071 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Open-label, Non-comparative Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Candidiasis or Candidemia (CFDA Commitment)
Lead sponsor
Astellas Pharma China, Inc.
Phase
Phase 4
Overall status
Terminated
Start date
September 26, 2013
Completion date
August 28, 2015
Enrollment
59 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

candidemia, candidiasis